Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Florida
Hoffmann-La Roche
Endeavor Biomedicines, Inc.
M.D. Anderson Cancer Center
Emory University
Eastern Cooperative Oncology Group
EMD Serono
Essen Biotech